Literature DB >> 16583435

Association of AKT1 haplotype with the risk of schizophrenia in Iranian population.

Sepideh N Bajestan1, Amir H Sabouri, Masayuki Nakamura, Hiroshi Takashima, Mohammad R Keikhaee, Fatemeh Behdani, Mohammad R Fayyazi, Mohammad R Sargolzaee, Mahboobeh N Bajestan, Zahra Sabouri, Esmaeil Khayami, Sima Haghighi, Susan B Hashemi, Nobutaka Eiraku, Hamid Tufani, Hossein Najmabadi, Kimiyoshi Arimura, Akira Sano, Mitsuhiro Osame.   

Abstract

AKT-glycogen synthase kinase 3beta (GSK3beta) signaling is a target of lithium and has been implicated in the pathogenesis of mood disorders and schizophrenia. AKT1 protein level is decreased in the peripheral lymphocytes and brains of schizophrenic patients. The SNP2/3/4 TCG haplotype of AKT1 was associated with schizophrenia in patients with Northern European origin. In the present study, we genotyped five single nucleotide polymorphisms (SNP1-5) of AKT1 gene according to the original study in Iranians comprising of 321 schizophrenic patients and 383 controls, all residing in Mashhad city, Northeastern Iran. Haplotype analysis showed that the frequency of a five-SNP haplotype (AGCAG) was significantly higher in schizophrenic patients (0.068) than that of controls (0.034) (P = 0.03 after Bonferroni correction, OR = 2.04, CI = 1.2-3.4). In stratified analysis by schizophrenia subtypes, the frequency of the same haplotype was significantly higher in disorganized subtype (n = 78, frequency of haplotype=0.081) when compared with normal controls (P = 0.04 after Bonferroni correction, OR = 2.59, CI = 1.3-5.2). Our findings did not confirm the association of AKT1 SNP2/3/4 TCG haplotype with the risk of schizophrenia as reported in the original study but showed the evidence of association with a different haplotype, AKT1 five-SNP AGCAG haplotype, with the risk of schizophrenia in Iranian population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16583435     DOI: 10.1002/ajmg.b.30291

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  29 in total

1.  Akt-dependent and isoform-specific regulation of dopamine transporter cell surface expression.

Authors:  Nicole K Speed; Heinrich J G Matthies; J Phillip Kennedy; Roxanne A Vaughan; Jonathan A Javitch; Scott J Russo; Craig W Lindsley; Kevin Niswender; Aurelio Galli
Journal:  ACS Chem Neurosci       Date:  2010-05-25       Impact factor: 4.418

2.  DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

3.  Quantitative trait loci linked to thalamus and cortex gray matter volumes in BXD recombinant inbred mice.

Authors:  H Dong; M V Martin; J Colvin; Z Ali; L Wang; L Lu; R W Williams; G D Rosen; J G Csernansky; J M Cheverud
Journal:  Heredity (Edinb)       Date:  2007-04-04       Impact factor: 3.821

4.  Functional characterization of a haplotype in the AKT1 gene associated with glucose homeostasis and metabolic syndrome.

Authors:  Brennan T Harmon; Stephanie A Devaney; Heather Gordish-Dressman; Erica K Reeves; Po Zhao; Joseph M Devaney; Eric P Hoffman
Journal:  Hum Genet       Date:  2010-09-26       Impact factor: 4.132

5.  Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia.

Authors:  Tiffany A Greenwood; Laura C Lazzeroni; Sarah S Murray; Kristin S Cadenhead; Monica E Calkins; Dorcas J Dobie; Michael F Green; Raquel E Gur; Ruben C Gur; Gary Hardiman; John R Kelsoe; Sherry Leonard; Gregory A Light; Keith H Nuechterlein; Ann Olincy; Allen D Radant; Nicholas J Schork; Larry J Seidman; Larry J Siever; Jeremy M Silverman; William S Stone; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; Robert Freedman; David L Braff
Journal:  Am J Psychiatry       Date:  2011-04-15       Impact factor: 18.112

6.  AKT1 G205T genotype influences obesity-related metabolic phenotypes and their responses to aerobic exercise training in older Caucasians.

Authors:  Jennifer A McKenzie; Sarah Witkowski; Andrew T Ludlow; Stephen M Roth; James M Hagberg
Journal:  Exp Physiol       Date:  2010-11-19       Impact factor: 2.969

Review 7.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

8.  Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function.

Authors:  Darrick T Balu; Gregory C Carlson; Konrad Talbot; Hala Kazi; Tiffany E Hill-Smith; Rachel M Easton; Morris J Birnbaum; Irwin Lucki
Journal:  Hippocampus       Date:  2010-11-03       Impact factor: 3.899

Review 9.  BDNF-TrkB signaling and neuroprotection in schizophrenia.

Authors:  Chirayu D Pandya; Ammar Kutiyanawalla; Anilkumar Pillai
Journal:  Asian J Psychiatr       Date:  2012-11-03

10.  AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families.

Authors:  Dawn L Thiselton; Vladimir I Vladimirov; Po-Hsiu Kuo; Joseph McClay; Brandon Wormley; Ayman Fanous; Francis A O'Neill; Dermot Walsh; Edwin J C G Van den Oord; Kenneth S Kendler; Brien P Riley
Journal:  Biol Psychiatry       Date:  2007-09-06       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.